SCHEMBL2208077

SCHEMBL2208077

CCOC(=O)C(C)=Cc1ccc(OC)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.54
MEN1 O00255 5/20 0.54
KMT2A Q03164 5/20 0.54
LMNA P02545 2/20 0.54
NPSR1 Q6W5P4 2/20 0.54
S1PR4 O95977 1/20 0.54
S1PR1 P21453 1/20 0.54
MAPK1 P28482 1/20 0.54
CYP1A2 P05177 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
ALDH1A1 P00352 5/20 0.48
KDM4E B2RXH2 3/20 0.48
HPGD P15428 2/20 0.48
HSP90AA1 P07900 1/20 0.48
NR1H4 Q96RI1 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
GSK3B P49841 1/20 0.46
F3 P13726 1/20 0.45
MAOB P27338 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2208074 1.00 MAPT (0.54) MAPTMEN1KMT2ALMNANPSR1
SCHEMBL13781587 0.87 ALDH1A1 (0.45) MAPTMEN1KMT2ALMNANPSR1
SCHEMBL27463291 0.86 CYP1A2 (0.46) MAPTKMT2ALMNANPSR1CYP1A2
SCHEMBL438314 0.85 MEN1 (0.70) MAPTMEN1KMT2ALMNANPSR1
SCHEMBL3609468 0.85 MAPT (0.58) MAPTMEN1KMT2ALMNANPSR1
SCHEMBL3609471 0.85 MAPT (0.58) MAPTMEN1KMT2ALMNANPSR1
SCHEMBL10851473 0.84 KMT2A (0.66) MAPTMEN1KMT2ALMNANPSR1
SCHEMBL30553780 0.84 KMT2A (0.66) MAPTMEN1KMT2ALMNANPSR1
SCHEMBL10851464 0.84 KMT2A (0.66) MAPTMEN1KMT2ALMNANPSR1
SCHEMBL13916941 0.84 MAPT (0.50) MAPTMEN1KMT2ALMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109704926-B Anticancer active molecular skeleton 1, 4-eneyne compound and preparation method and application thereof 南京工业大学 2022-02-08 CN claimed
CN-109970560-A Preparation method of tri-substituted 1, 3-diene compound 南京工业大学 2019-07-05 CN claimed
CN-109704926-A Anticancer active molecular skeleton 1, 4-eneyne compound and preparation method and application thereof 南京工业大学 2019-05-03 CN claimed
CN-109704926-B Anticancer active molecular skeleton 1, 4-eneyne compound and preparation method and application thereof 南京工业大学 2022-02-08 CN disclosed
US-7982064-B2 Method for preparing ortho-substituted aminoferrocenes BROCK UNIVERSITY (CA) 2011-07-19 US disclosed
US-20100137588-A1 METHOD FOR PREPARING ORTHO-SUBSTITUTED AMINOFERROCENES BROCK UNIVERSITY (CA) 2010-06-03 US disclosed
US-4061771-A Ethynylindenyl compounds and derivatives thereof used in the treatment of pain, fever and inflammation WILLIAM H. RORER, INC. (US) 1977-12-06 US disclosed
US-3983253-A Ethynylindenyl compounds and derivatives thereof used in the treatment of pain, fever and inflammation WILLIAM H. RORER, INC. (US) 1976-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137588-A1 METHOD FOR PREPARING ORTHO-SUBSTITUTED AMINOFERROCENES LPO, AOC1, AOC2 MAPT 4511/4885MEN1 2900/4885KMT2A 3110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.